|

Ipilimumab N01 Clinical Trials

2 actively recruiting trials

Also known as: IBI-310

Pipeline

Phase 2: 2

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital2

Indications

  • Cancer2
  • Conversion Therapy1
  • Ipilimumab N011
  • Dabrafenib1
  • MSS (Microsatellite Stable)1

Other2 trials

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Phase 2
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.